Remdesivir: The Drug That Might End The Covid-19 Pandemic

Coronavirus outbreak has caused a global pandemic resulting in one million of infections and lakhs of deaths worldwide. With a vaccine expected to be a year or more away, scientists are looking for existing treatments that can cure the virus. According to a study published in Science magazine, a new drug called remdesivir is showing good results against covid-19 treatment.

Scientists believe that Remdesivir is going to be a game changer

The study has shown that the drug prevents the virus from mutation. The virus of Sars-Cov-2 is a strand of RNA. To replicate this, it needs something else to function as a parasite. In which scientists have found a function of the RNA-dependent RNA polymerase (RDRp), which is similar to Ebola and Hepatitis C virus. The Remdesivir drug, which works in the RdRp, hopes to work for the corona virus.

In the article titled “Structure of the RNA-Dependent RNA Polymerase (RDRp) from COVID-19 Virus“, researchers have described the molecular interactions between the coronavirus, RdRp and Remdesivir drug.

Clinical trial:

The drug, which is still subject to continuing clinical trials, has shown positive early effects in a trial. The drug used as a trial for 2,400 patients with severe Covid-19 symptoms at 152 test centers around the world. Similarly, the drug tested in 169 hospitals and clinics around the world with 1,600 patients with mild to moderate symptoms. During the test, Patients had severe respiratory symptoms and fever. But they were able to leave the hospital after less than a week of treatment. Gilead has said it is ready to accessible the Remdesivir by the end of this month.

Remedicavir, currently manufactured by US pharma company Gilead, is not available in India. However Remdesivir is not yet licenced or accepted internationally anywhere. Also it has not yet been proven to be safe or successful for COVID-19 treatment.

Also read: BCG Vaccine and Coronavirus — what is the connection?

Leave a Reply

Your email address will not be published. Required fields are marked *